Anzeige
Mehr »
Login
Freitag, 07.10.2022 Börsentäglich über 12.000 News von 678 internationalen Medien
STRONG BUY! Clear Sky Lithium zündet jetzt den Turbo!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 502816 ISIN: GB0009223206 Ticker-Symbol: NPW1 
Tradegate
05.10.22
20:54 Uhr
11,900 Euro
+0,100
+0,85 %
1-Jahres-Chart
SMITH & NEPHEW PLC Chart 1 Jahr
5-Tage-Chart
SMITH & NEPHEW PLC 5-Tage-Chart
RealtimeGeldBriefZeit
11,75011,95006.10.
11,75011,90006.10.
PR Newswire
421 Leser
Artikel bewerten:
(2)

Smith & Nephew plc: Smith+Nephew announces new UK R&D and manufacturing facility for Advanced Wound Management with $100m+ investment near Hull

LONDON, June 9, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN,NYSE:SNN), the global medical technology business, today announces that it is to build a new R&D and manufacturing facility for its Advanced Wound Management franchise on the outskirts of Hull, UK.

Smith+Nephew logo

Smith+Nephew will invest more than $100 million to create a world-class R&D, manufacturing and flexible office environment. The development will also be supported by a grant from UK Government. The new facility is expected to support more than $10 billion of sales in its first ten years of operation.

Simon Fraser, President of Advanced Wound Management, Smith+Nephew, said: "This major investment demonstrates our commitment to the UK and to building our leadership in Advanced Wound Management. Our vision is for a world-class working environment that encourages innovation and collaboration to deliver next-generation products that improve the standard of care for the NHS and customers around the world. Smith+Nephew was founded in Hull in 1856 and we are proud to make this major investment in the region for future generations."

Lord Grimstone, Minister for Investment, said:
"As set out in our Life Sciences Vision, we are committed to harnessing our skilled workforce and existing strengths in R&D to continue to attract large scale manufacturing and the economic opportunities that come with them. Today's announcement from Smith+Nephew is a major vote of confidence in our thriving Life Sciences sector, cementing the UK's status as a global science superpower and helping us to level up economic growth across the country."

Lord Kamall, Minister for Innovation, said:
"Life sciences are crucial to transforming our health service and ensure the NHS is able to deliver world-class care. Coupled with health research, it has been vital in our fight against Covid and in saving thousands of lives through the rapid creation of vaccines and identifying life-saving treatments like dexamethasone. Smith+Nephew's new R&D base will ensure the UK remains at the forefront of life sciences and innovative research, levelling up the health of our nation, tackling disparities and saving lives."

Subject to planning approval, the new facility will be at Melton West business park (HU14 3RS) approximately eight miles from Smith+Nephew's current Hull site, which it will replace and where we have been located for more than 100 years.

The Advanced Wound Management R&D programme will benefit from advanced laboratories better able to support the development of new technologies to satisfy unmet clinical needs. This ensures that the UK remains one of the world's leading wound care R&D locations.

Manufacturing will focus on the production of high-technology products, supporting the fast and efficient launches of new products, and manufacturing complex materials used across Smith+Nephew's portfolio.

The new facility will be designed to high sustainability standards with a focus on energy and resource efficiency. Working with regulators, we will utilize the Best Available Techniques within our processes to minimize or prevent impact to the environment from our operations.

Melton West business park is the closest available suitable site to our current Hull facility. It offers the size and established infrastructure to accommodate the new facility and is allocated under the East Riding of Yorkshire Local Plan for developments of this kind.

Dominic Gibbons, Managing Director of Hull-based Wykeland Group, owner and developer of Melton West, said:
"We are delighted the strategic, long-term investments we have made in the infrastructure at Melton West business park have enabled Smith+Nephew to stay within the region and make such a huge investment in a state-of-the-art new facility. Smith+Nephew is one of the region's leading employers, with a proud local history and heritage. This investment will open an exciting new chapter in that story."

The new site is expected to open in 2024. Smith+Nephew worked closely with Hull City Council but unfortunately were unable to find an appropriately sized and deliverable site within the city. Smith+Nephew is committed to continuing to work with the City Council and other stakeholders regarding future options for the current Hull site.

Background - Smith+Nephew in Hull

Smith+Nephew was founded in Hull in 1856, and our Advanced Wound Management business has a long track record of developing pioneering products here. In recent times these included PICO, the world's first single-use Negative Pressure Wound Therapy System and the leading ALLEVYN Life Foam Dressing family.

Smith+Nephew's collaboration with the University of Hull has created one of the world's largest Wound Care Research Clusters, including eight multi-disciplinary PhD studentships.

Smith+Nephew is also an active member in the local community, including being a co-founder and sponsor of the Ron Dearing University Technical College, offering STEM students a unique, employer-led education.

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID; economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers (including, without limitation, as a result of COVID); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cyber security; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

Logo - https://mma.prnewswire.com/media/3924/Smith_Nephew_Logo.jpg

SMITH & NEPHEW-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2022 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.